• Corcept Therapeutics has resubmitted its New Drug Application to the FDA for relacorilant as a treatment for Cushing’s syndrome, incorporating additional analyses from the GRACE, GRADIENT and other supporting studies after an earlier regulatory request.
• This move highlights Corcept’s effort to broaden its treatment portfolio beyond Korlym, potentially changing how hypercortisolism is managed in clinical practice.
• We’ll now examine how the relacorilant NDA resubmission, and its potential to reduce single-drug dependence, affects Corcept’s investment narrative.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Corcept Therapeutics Investment Narrative Recap

To own Corcept today, you have to believe its cortisol modulation franchise can grow beyond Korlym and withstand intensifying generic, pricing and legal pressures. The relacorilant NDA resubmission is now the key near term catalyst, while the biggest risk is that any further FDA setbacks would prolong single product dependence and keep earnings more exposed to Korlym’s pricing and volume headwinds.

The recent CATALYST and MOMENTUM data tie directly into this story. By highlighting how often hypercortisolism appears in difficult type 2 diabetes and resistant hypertension, these trials support the idea of a much larger diagnosable patient pool, which could matter even more if relacorilant is cleared for Cushing’s and Corcept can pivot part of that demand away from Korlym.

Yet in contrast, investors should also be aware that...

Corcept Therapeutics’ narrative projects $1.9 billion revenue and $910.1 million earnings by 2029.

Uncover how Corcept Therapeutics' forecasts yield a $88.00 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Before this resubmission, the most bullish analysts were projecting Corcept’s revenue to reach about US$1.9 billion and earnings around US$708 million by 2029, so if you lean on those forecasts you are effectively embracing a far more optimistic view of relacorilant’s multi indication approvals and uptake than the baseline narrative, and this latest FDA development could either reinforce or challenge that stance once the outcome is known.

Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.